Details of the Drug Combinations

General Information of This Drug (ID: DMX2OMJ)

Drug Name
Immune globulin   DMX2OMJ
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1]
Bone marrow transplantation QB63.6 Approved [2]
Immune System disease 4A01-4B41 Approved [2]
Immunodeficiency 4A00-4A85 Approved [2]
Virus infection 1A24-1D9Z Approved [2]
Nervous system paraneoplastic or autoimmune disorders 8E4A.1 Phase 3 [3]
Pediatric cancer 2A00-2F9Z Phase 2 [4]
Bacillus anthracis infection 1G40 Phase 1 [5]
⏷ Show the Full List of Indication(s)

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Immune globulin + CJC-1295 DC71T6Y CJC-1295 Alzheimer disease [6]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Octapharma.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT00448253) Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum. U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)